|
|
Article: Pevion Gets $29M For Vaccine Pipeline.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BioWorld Today Correspondent
Pevion Biotech AG raised CHF35 million (US$29.3 million) in a Series A round to take forward a pipeline of virosome-based vaccine candidates for infectious disease and cancer.
The Bern, Switzerland-based company, which was established as a 50-50 joint venture in 2002 between Berna Biotech AG (now part of Leiden, the Netherlands-based Crucell NV) and Bubendorf, Switzerland-based Bachem Group AG, previously raised CHF20 million from its founders.
The new cash is earmarked for two of its three clinical stage programs, as well as several earlier-stage projects. However, its new investors passed on its most advanced ...